| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ZNF22 |
| Uniprot No | P17026 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-224 aa |
| 活性数据 | MRLAKPKAGI SRSSSQGKAY ENKRKTGRQR QKWGMTIRFD SSFSRLRRSL DDKPYKCTEC EKSFSQSSTL FQHQKIHTGK KSHKCADCGK SFFQSSNLIQ HRRIHTGEKP YKCDECGESF KQSSNLIQHQ RIHTGEKPYQ CDECGRCFSQ SSHLIQHQRT HTGEKPYQCS ECGKCFSQSS HLRQHMKVHK EEKPRKTRGK NIRVKTHLPS WKAGTGRKSV AGLR |
| 分子量 | 25.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人ZNF22蛋白的参考文献示例(仅供参考，具体文献需通过学术数据库查询)：
---
1. **文献名称**: *"Functional characterization of recombinant human ZNF22 as a transcriptional repressor in cancer cell lines"*
**作者**: Smith J, et al.
**摘要**: 研究报道了重组人ZNF22蛋白的制备及其在肺癌细胞中的转录抑制功能。实验表明，ZNF22通过结合启动子区域的GC富集序列，抑制肿瘤相关基因表达，并减缓细胞增殖。
2. **文献名称**: *"Structural analysis of the zinc finger domain in human ZNF22 and implications for DNA binding"*
**作者**: Lee H, et al.
**摘要**: 通过重组表达和晶体结构解析，揭示了ZNF22锌指结构域与DNA结合的关键位点，并发现其C末端区域对转录调控具有调控作用，为设计靶向疗法提供结构基础。
3. **文献名称**: *"ZNF22 overexpression induces apoptosis in gastric cancer cells via regulation of BAX/Bcl-2 pathway"*
**作者**: Zhang Y, et al.
**摘要**: 研究发现重组ZNF22蛋白在胃癌细胞中通过上调促凋亡蛋白BAX并抑制Bcl-2.诱导线粒体依赖性凋亡，提示其潜在的抑癌功能。
4. **文献名称**: *"Recombinant ZNF22 inhibits epithelial-mesenchymal transition by modulating TGF-β signaling in breast cancer"*
**作者**: Wang R, et al.
**摘要**: 研究证明重组ZNF22蛋白通过干扰TGF-β/Smad信号通路，抑制乳腺癌细胞上皮间质转化(EMT)，降低迁移和侵袭能力。
---
**注意**：以上文献为示例性概括，实际研究中需通过PubMed、Web of Science等平台检索真实文献。建议结合关键词“ZNF22 recombinant protein”“transcriptional regulation”“cancer”等进一步筛选。
Zinc finger protein 22 (ZNF22), a member of the zinc finger protein family, is a transcription regulatory factor characterized by conserved C₂H₂-type zinc finger domains. These domains enable sequence-specific DNA binding, allowing ZNF22 to modulate gene expression by interacting with target promoters or repressors. It is ubiquitously expressed in human tissues and implicated in critical cellular processes, including proliferation, differentiation, and apoptosis. The KRAB (Krüppel-associated box) domain in its N-terminal region facilitates interactions with co-repressors, suggesting a role in transcriptional repression.
Recombinant human ZNF22 protein is engineered via heterologous expression systems, such as *E. coli* or mammalian cell lines, followed by affinity purification (e.g., His-tag or GST-tag systems). This protein serves as a vital tool for elucidating its biological functions, structure-function relationships, and interaction networks. Studies have linked ZNF22 dysregulation to cancers, neurodevelopmental disorders, and immune responses, though its precise molecular mechanisms remain unclear. Current research focuses on deciphering its target genes, signaling pathways, and epigenetic regulatory roles, aiming to explore therapeutic potential. Advances in recombinant technology have enabled high-purity ZNF22 production, accelerating functional studies and drug discovery efforts.
×
